| ID Source | ID |
|---|---|
| PubMed CID | 155166 |
| CHEMBL ID | 1568307 |
| CHEBI ID | 81534 |
| SCHEMBL ID | 14938634 |
| MeSH ID | M0456253 |
| Synonym |
|---|
| bde-153 |
| NCGC00090916-01 |
| 68631-49-2 |
| 2,2',4,4',5,5'-hexabromodiphenyl ether |
| smr000568459 |
| MLS001065604 |
| 1,1'-oxybis(2,4,5-tribromobenzene) |
| 1,2,4-tribromo-5-(2,4,5-tribromophenoxy)benzene |
| bde 153 |
| C18137 |
| HMS3039L14 |
| tox21_202469 |
| dtxcid2010047 |
| cas-68631-49-2 |
| NCGC00260018-01 |
| dtxsid4030047 , |
| 2,2',4,4',5,5'-hexabde |
| unii-nx58wcq511 |
| pbde 153 |
| benzene, 1,1'-oxybis(2,4,5-tribromo- |
| nx58wcq511 , |
| benzene, 1,1'-oxybis[2,4,5-tribromo- |
| CHEBI:81534 , |
| CHEMBL1568307 |
| SCHEMBL14938634 |
| RZXIRSKYBISPGF-UHFFFAOYSA-N |
| 1,1'-oxybis(2,4,5-tribromo-benzene |
| 1,1'-oxybis[2,4,5-tribromo]benzene, 9ci |
| Q27155450 |
| 5,5'-oxybis(1,2,4-tribromobenzene) |
| benzene, 1,1'-oxybis[2,4,5-tribromo-; 1,1'-oxybis[2,4,5-tribromobenzene]; 2,2',4,4',5,5'-hexabromodiphenyl ether; bde 153; pbde 153; 2,2',4,4',5,5'-hexabde |
| pbde no. 153 |
| pbde 153 50 microg/ml in nonane |
| Class | Description |
|---|---|
| organobromine compound | A compound containing at least one carbon-bromine bond. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 15.8562 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 30.0772 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 29.8675 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 13.3413 | 0.0010 | 22.6508 | 76.6163 | AID1224838 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 11.8905 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 25.1189 | 0.0008 | 17.5051 | 59.3239 | AID588544 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 17.3436 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID588527; AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 29.8675 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 21.9964 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID588514 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 25.3639 | 0.0010 | 24.5048 | 61.6448 | AID588535; AID743212; AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 22.3872 | 0.0010 | 19.4141 | 70.9645 | AID588536 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 33.3314 | 0.0237 | 23.2282 | 63.5986 | AID588543; AID743222 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 33.5119 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 24.0908 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 17.7828 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 26.8522 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 66.8242 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| geminin | Homo sapiens (human) | Potency | 9.1218 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 1.0000 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 29.8675 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 17.4351 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 29.8675 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 42.1632 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||